✦ June 6: The FDA approved two new methods of administration for Nucala (mepolizumab) — an autoinjector and a prefilled syringe — to treat severe eosinophilic asthma or eosinophilic granulomatosis with polyangiitis. Dosing of the GlaxoSmithKline interleukin (IL)-5 inhibitor is once every four weeks.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.